Literature DB >> 20334368

Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.

Philipp Y Maximov1, Cynthia B Myers, Ramona F Curpan, Joan S Lewis-Wambi, V Craig Jordan.   

Abstract

Estrogens can potentially be classified into planar (class I) or nonplanar (class II) categories, which might have biological consequences. 1,1,2-Triphenylethylene (TPE) derivatives were synthesized and evaluated against 17beta-estradiol (E2) for their estrogenic activity in MCF-7 human breast cancer cells. All TPEs were estrogenic and, unlike 4-hydroxytamoxifen (4OHTAM) and Endoxifen, induced cell growth to a level comparable to that of E2. All the TPEs increased ERE activity in MCF-7:WS8 cells with the order of potency as followed: E2 > 1,1-bis(4,4'-hydroxyphenyl)-2-phenylbut-1-ene (15) > 1,1,2-tris(4-hydroxyphenyl)but-1-ene (3) > Z 4-(1-(4-hydroxyphenyl)-1-phenylbut-1-en-2-yl)phenol (7) > E 4-(1-(4-hydroxyphenyl)-1-phenylbut-1-en-2-yl)phenol (6) > Z(4-(1-(4-ethoxyphenyl)-1-(4-hydroxyphenyl)but-1-en-2-yl)phenol (12) > 4-OHTAM. Transient transfection of the ER-negative breast cancer cell line T47D:C4:2 with wild-type ER or D351G ER mutant revealed that all of the TPEs increased ERE activity in the cells expressing the wild-type ER but not the mutant, thus confirming the importance of Asp351 for ER activation by the TPEs. The findings confirm E2 as a class I estrogen and the TPEs as class II estrogens. Using available conformations of the ER liganded with 4OHTAM or diethylstilbestrol, the TPEs optimally occupy the 4OHTAM ER conformation that expresses Asp351.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334368      PMCID: PMC2867604          DOI: 10.1021/jm901907u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.

Authors:  A S Levenson; V C Jordan
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 12.701

3.  Molecular classification of estrogens.

Authors:  V C Jordan; J M Schafer; A S Levenson; H Liu; K M Pease; L A Simons; J W Zapf
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.

Authors:  A S Levenson; W H Catherino; V C Jordan
Journal:  J Steroid Biochem Mol Biol       Date:  1997-03       Impact factor: 4.292

5.  Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.

Authors:  Veronika Lubczyk; Helmut Bachmann; Ronald Gust
Journal:  J Med Chem       Date:  2002-11-21       Impact factor: 7.446

Review 6.  Role of hormones in mammary cancer initiation and progression.

Authors:  I H Russo; J Russo
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

7.  Investigations of new lead structures for the design of selective estrogen receptor modulators.

Authors:  R Gust; R Keilitz; K Schmidt
Journal:  J Med Chem       Date:  2001-06-07       Impact factor: 7.446

8.  Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351.

Authors:  A S Levenson; J I MacGregor Schafer; D J Bentrem; K M Pease; V C Jordan
Journal:  J Steroid Biochem Mol Biol       Date:  2001 Jan-Mar       Impact factor: 4.292

9.  Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.

Authors:  J MacGregor Schafer; H Liu; D J Bentrem; J W Zapf; V C Jordan
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

10.  Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens.

Authors:  David Bentrem; Jennifer E Fox; Sandra Timm Pearce; Hong Liu; Sam Pappas; David Kupfer; James W Zapf; V Craig Jordan
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

View more
  25 in total

1.  The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Authors:  V Craig Jordan; Ifeyinwa Obiorah; Ping Fan; Helen R Kim; Eric Ariazi; Heather Cunliffe; Hiltrud Brauch
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

2.  The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

Authors:  Joan S Lewis-Wambi; Helen Kim; Ramona Curpan; Ronald Grigg; Mohammed A Sarker; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2011-07-07       Impact factor: 4.436

3.  Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer.

Authors:  Ifeyinwa Obiorah; Surojeet Sengupta; Ramona Curpan; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

4.  The Conformation of the Estrogen Receptor Directs Estrogen-Induced Apoptosis in Breast Cancer: A Hypothesis.

Authors:  Philipp Maximov; Surojeet Sengupta; Joan S Lewis-Wambi; Helen R Kim; Ramona F Curpan; V Craig Jordan
Journal:  Horm Mol Biol Clin Investig       Date:  2011-03-01

Review 5.  The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Authors:  Ping Fan; Philipp Y Maximov; Ramona F Curpan; Balkees Abderrahman; V Craig Jordan
Journal:  Mol Cell Endocrinol       Date:  2015-06-05       Impact factor: 4.102

6.  Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

Authors:  I E Obiorah; V C Jordan
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

7.  In vitro and in vivo effects of tamoxifen against larval stage Echinococcus granulosus.

Authors:  María Celeste Nicolao; María Celina Elissondo; Guillermo M Denegri; Alejandra B Goya; Andrea C Cumino
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

8.  Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Authors:  Patrick M Kelly; Niall O Keely; Sandra A Bright; Bassem Yassin; Gloria Ana; Darren Fayne; Daniela M Zisterer; Mary J Meegan
Journal:  Molecules       Date:  2017-08-31       Impact factor: 4.411

9.  Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.

Authors:  S Sengupta; I Obiorah; P Y Maximov; R Curpan; V C Jordan
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality.

Authors:  Ifeyinwa Obiorah; V Craig Jordan
Journal:  Menopause       Date:  2013-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.